Back to trial

NCT02340221

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

Version 6 to 7 · Hoffmann-La Roche

Patch inspector

Version 6 to 7

9 operations 3 path groups ctgov_internal_history
ClinicalTrials.gov
Severity is deterministic uncalibrated triage metadata, not validated review priority. Operation-level severity is inferred from deterministic path rules. Rule matches shown per operation are approximate previews (they skip the pipeline's suppression passes); the authoritative classification is the stored event record.
Plain-language summary

Manual review pending.

Rules fired
secondary_outcome_any_change
Value signals

None recorded.

Provenance
Source
ctgov_internal_history
Fetched
2026-06-18 19:11:43+00
Raw hash
93b859b48a9568179878f505c9e2db7fe38f1dc8d222e681778caf22f800546b
Payload
Source URL
Secondary outcomes Additional endpoints and outcome descriptions. Triage: High 1 ops
replace /protocolSection/outcomesModule/secondaryOutcomes/1/measure
Triage: High
Secondary Outcome Change Operation 4
Matched rules
  • secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.
Before
Overall objective response (partial response [PR] plus complete response [CR]), as determined by using RECIST v.1.1
After
Overall objective response rate (partial response [PR] plus complete response [CR]), as determined by using RECIST v.1.1
Contacts and locations Site, contact, and location updates that are usually operational. Triage: Uncategorized 5 ops
add /protocolSection/contactsLocationsModule/locations/75
Triage: Uncategorized
Uncategorized Operation 5
After
{
  "zip": "23007",
  "city": "Jaén",
  "state": "Jaen",
  "status": "NOT_YET_RECRUITING",
  "country": "Spain",
  "geoPoint": {
    "lat": 37.76922,
    "lon": -3.79028
  }
}
add /protocolSection/contactsLocationsModule/locations/78
Triage: Uncategorized
Uncategorized Operation 6
After
{
  "zip": "28033",
  "city": "Madrid",
  "state": "Madrid",
  "status": "NOT_YET_RECRUITING",
  "country": "Spain",
  "geoPoint": {
    "lat": 40.4165,
    "lon": -3.70256
  }
}
add /protocolSection/contactsLocationsModule/locations/79
Triage: Uncategorized
Uncategorized Operation 7
After
{
  "zip": "38320",
  "city": "San Cristóbal de La Laguna",
  "state": "Tenerife",
  "status": "NOT_YET_RECRUITING",
  "country": "Spain",
  "geoPoint": {
    "lat": 28.4853,
    "lon": -16.32014
  }
}
add /protocolSection/contactsLocationsModule/locations/80
Triage: Uncategorized
Uncategorized Operation 8
After
{
  "zip": "46980",
  "city": "Valencia",
  "state": "Valencia",
  "status": "NOT_YET_RECRUITING",
  "country": "Spain",
  "geoPoint": {
    "lat": 39.47391,
    "lon": -0.37966
  }
}
add /protocolSection/contactsLocationsModule/locations/81
Triage: Uncategorized
Uncategorized Operation 9
After
{
  "zip": "48903",
  "city": "Barakaldo",
  "state": "Vizcaya",
  "status": "RECRUITING",
  "country": "Spain",
  "geoPoint": {
    "lat": 43.29639,
    "lon": -2.98813
  }
}
Other registry fields Changes outside the current high-signal rule families. Triage: Uncategorized 3 ops
replace /protocolSection/statusModule/lastUpdateSubmitDate
Triage: Uncategorized
Uncategorized Operation 1
Before
2015-03-09
After
2015-03-16
replace /protocolSection/statusModule/lastUpdatePostDateStruct/date
Triage: Uncategorized
Uncategorized Operation 2
Before
2015-03-10
After
2015-03-17
replace /protocolSection/descriptionModule/briefSummary
Triage: Uncategorized
Uncategorized Operation 3
Before
This international, multicenter, randomized, double-blinded, placebo-controlled study is designed to compare the efficacy and safety of taselisib + fulvestrant with that of placebo + fulvestrant in postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative, PIK3CA-mutant, unresectable, locally advanced or metastatic breast cancer after recurrence or progression during or after an aromatase inhibitor (AI) therapy.
The anticipated duration of the study is approximately 3.5 years.
After
This international, multicenter, randomized, double-blinded, placebo-controlled study is designed to compare the efficacy and safety of taselisib + fulvestrant with that of placebo + fulvestrant in postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative, PIK3CA-mutant, unresectable, locally advanced or metastatic breast cancer after recurrence or progression during or after an aromatase inhibitor (AI) therapy.
There will be a 2:1 randomization to the taselisib arm versus the placebo arm.
Enrollment will be enriched for patients with PIK3CA mutant tumors via central testing.
The anticipated duration of the study is approximately 3.5 years.
Raw JSON Patch
[
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/lastUpdateSubmitDate",
    "value": "2015-03-16"
  },
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/lastUpdatePostDateStruct/date",
    "value": "2015-03-17"
  },
  {
    "op": "replace",
    "path": "/protocolSection/descriptionModule/briefSummary",
    "value": "This international, multicenter, randomized, double-blinded, placebo-controlled study is designed to compare the efficacy and safety of taselisib + fulvestrant with that of placebo + fulvestrant in postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative, PIK3CA-mutant, unresectable, locally advanced or metastatic breast cancer after recurrence or progression during or after an aromatase inhibitor (AI) therapy.\nThere will be a 2:1 randomization to the taselisib arm versus the placebo arm.\nEnrollment will be enriched for patients with PIK3CA mutant tumors via central testing.\nThe anticipated duration of the study is approximately 3.5 years."
  },
  {
    "op": "replace",
    "path": "/protocolSection/outcomesModule/secondaryOutcomes/1/measure",
    "value": "Overall objective response rate (partial response [PR] plus complete response [CR]), as determined by using RECIST v.1.1"
  },
  {
    "op": "add",
    "path": "/protocolSection/contactsLocationsModule/locations/75",
    "value": {
      "zip": "23007",
      "city": "Jaén",
      "state": "Jaen",
      "status": "NOT_YET_RECRUITING",
      "country": "Spain",
      "geoPoint": {
        "lat": 37.76922,
        "lon": -3.79028
      }
    }
  },
  {
    "op": "add",
    "path": "/protocolSection/contactsLocationsModule/locations/78",
    "value": {
      "zip": "28033",
      "city": "Madrid",
      "state": "Madrid",
      "status": "NOT_YET_RECRUITING",
      "country": "Spain",
      "geoPoint": {
        "lat": 40.4165,
        "lon": -3.70256
      }
    }
  },
  {
    "op": "add",
    "path": "/protocolSection/contactsLocationsModule/locations/79",
    "value": {
      "zip": "38320",
      "city": "San Cristóbal de La Laguna",
      "state": "Tenerife",
      "status": "NOT_YET_RECRUITING",
      "country": "Spain",
      "geoPoint": {
        "lat": 28.4853,
        "lon": -16.32014
      }
    }
  },
  {
    "op": "add",
    "path": "/protocolSection/contactsLocationsModule/locations/80",
    "value": {
      "zip": "46980",
      "city": "Valencia",
      "state": "Valencia",
      "status": "NOT_YET_RECRUITING",
      "country": "Spain",
      "geoPoint": {
        "lat": 39.47391,
        "lon": -0.37966
      }
    }
  },
  {
    "op": "add",
    "path": "/protocolSection/contactsLocationsModule/locations/81",
    "value": {
      "zip": "48903",
      "city": "Barakaldo",
      "state": "Vizcaya",
      "status": "RECRUITING",
      "country": "Spain",
      "geoPoint": {
        "lat": 43.29639,
        "lon": -2.98813
      }
    }
  }
]